Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy.
about
Oncolytic reovirus inhibits angiogenesis through induction of CXCL10/IP-10 and abrogation of HIF activity in soft tissue sarcomas.Emerging immune targets for the treatment of multiple myeloma.Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway.Potential of oncolytic viruses in the treatment of multiple myeloma.Current understanding of reovirus oncolysis mechanisms.Oncolytic Viruses for Multiple Myeloma Therapy.Going (Reo)Viral: Factors Promoting Successful Reoviral Oncolytic InfectionOncolytic virus and PD-1/PD-L1 blockade combination therapyOsteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1
P2860
Q47266341-F322E85C-7748-4663-9CB3-60E32345D52EQ50025144-E2EDC9AB-6A37-4625-9726-96CE541F7443Q52630284-70960391-9EE5-4CCC-8FA2-80665CF39F20Q52674773-7360A65E-7F08-4E20-974E-09BFC0B7FCBFQ55427397-B8EDE894-F49D-4CAC-8C71-DFAA99EFAE3EQ55515625-3D5B45B0-D4C7-4963-A092-9D40A989843CQ56986466-5AC935B7-D917-4C81-A276-1E5A3E8E0F91Q57174025-E0B4D834-0AE2-4BFB-B782-E2AC0279679BQ58790080-3C0CA28F-169E-42FC-A462-57BE25339F63
P2860
Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy.
@en
Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy.
@nl
type
label
Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy.
@en
Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy.
@nl
prefLabel
Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy.
@en
Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy.
@nl
P2093
P2860
P356
P1433
P1476
Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy.
@en
P2093
C M Calton
C M Espitia
S T Nawrocki
V Visconte
P2860
P2888
P304
P356
10.1038/LEU.2017.272
P50
P577
2017-08-23T00:00:00Z
P6179
1091308638